{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T11:22:50Z","timestamp":1789730570216,"version":"4.0.1"},"reference-count":59,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T00:00:00Z","timestamp":1762819200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA284593"],"award-info":[{"award-number":["R01CA284593"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30CA033572"],"award-info":[{"award-number":["P30CA033572"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Nucleic Acids"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.omtn.2025.102773","type":"journal-article","created":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T05:41:11Z","timestamp":1763444471000},"page":"102773","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Myeloid cell-targeted lipid nanoparticles for B cell lymphoma immunotherapy"],"prefix":"10.1016","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5444-1133","authenticated-orcid":false,"given":"Elaine Y.","family":"Kang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongfang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damian","family":"Kaniowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilson","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Swiderski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcin","family":"Kortylewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtn.2025.102773_bib1","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1007\/s00262-017-2036-5","article-title":"Regulatory myeloid cells: an underexplored continent in B-cell lymphomas","volume":"66","author":"Roussel","year":"2017","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.omtn.2025.102773_bib2","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1002\/ijc.35156","article-title":"The future of immunotherapy for diffuse large B-cell lymphoma","volume":"156","author":"Duell","year":"2025","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.omtn.2025.102773_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2025.116150","article-title":"Lipid nanoparticles as a tool to dissect dendritic cell maturation pathways","volume":"44","author":"Rennen","year":"2025","journal-title":"Cell Rep."},{"key":"10.1016\/j.omtn.2025.102773_bib4","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1038\/s41568-022-00546-2","article-title":"Therapeutic targeting of tumour myeloid cells","volume":"23","author":"Barry","year":"2023","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.omtn.2025.102773_bib5","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.943","article-title":"CD47-SIRP\u03b1 blocking-based immunotherapy: Current and prospective therapeutic strategies","volume":"12","author":"Bouwstra","year":"2022","journal-title":"Clin. Transl. Med."},{"key":"10.1016\/j.omtn.2025.102773_bib6","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1158\/2326-6066.CIR-22-0366","article-title":"Targeting the Siglec-Sialic Acid Immune Axis in Cancer: Current and Future Approaches","volume":"10","author":"L\u00e4ubli","year":"2022","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.omtn.2025.102773_bib7","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nri1995","article-title":"Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment","volume":"7","author":"Yu","year":"2007","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.omtn.2025.102773_bib8","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1007\/s00262-017-1966-2","article-title":"Myeloid cells as a target for oligonucleotide therapeutics: turning obstacles into opportunities","volume":"66","author":"Kortylewski","year":"2017","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.omtn.2025.102773_bib9","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/nature09671","article-title":"Oncogenically active MYD88 mutations in human lymphoma","volume":"470","author":"Ngo","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.omtn.2025.102773_bib10","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1182\/blood-2012-07-442590","article-title":"TLR9-mediated siRNA delivery for targeting of normal and malignant human hematopoietic cells in vivo","volume":"121","author":"Zhang","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.omtn.2025.102773_bib11","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.ymthe.2018.01.007","article-title":"B Cell Lymphoma Immunotherapy Using TLR9-Targeted Oligonucleotide STAT3 Inhibitors","volume":"26","author":"Zhao","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2025.102773_bib12","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.4049\/jimmunol.0902960","article-title":"Dendritic cell (DC)-specific targeting reveals Stat3 as a negative regulator of DC function","volume":"184","author":"Melillo","year":"2010","journal-title":"J. Immunol."},{"key":"10.1016\/j.omtn.2025.102773_bib13","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1038\/s41578-021-00358-0","article-title":"Lipid nanoparticles for mRNA delivery","volume":"6","author":"Hou","year":"2021","journal-title":"Nat. Rev. Mater."},{"key":"10.1016\/j.omtn.2025.102773_bib14","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1038\/s12276-023-01086-x","article-title":"Immunogenicity of lipid nanoparticles and its impact on the efficacy of mRNA vaccines and therapeutics","volume":"55","author":"Lee","year":"2023","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.omtn.2025.102773_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.copbio.2023.103049","article-title":"Immune response to the components of lipid nanoparticles for ribonucleic acid therapeutics","volume":"85","author":"Chen","year":"2024","journal-title":"Curr. Opin. Biotechnol."},{"key":"10.1016\/j.omtn.2025.102773_bib16","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s12943-020-01258-7","article-title":"Targeting STAT3 in cancer immunotherapy","volume":"19","author":"Zou","year":"2020","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.omtn.2025.102773_bib17","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.ccr.2008.12.018","article-title":"Regulation of the IL-23 and IL-12 balance by Stat3 signaling in the tumor microenvironment","volume":"15","author":"Kortylewski","year":"2009","journal-title":"Cancer Cell"},{"key":"10.1016\/j.omtn.2025.102773_bib18","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1038\/nbt.1564","article-title":"In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses","volume":"27","author":"Kortylewski","year":"2009","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.omtn.2025.102773_bib19","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.jconrel.2013.06.007","article-title":"Intracellular processing of immunostimulatory CpG-siRNA: Toll-like receptor 9 facilitates siRNA dicing and endosomal escape","volume":"170","author":"Nechaev","year":"2013","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.omtn.2025.102773_bib20","doi-asserted-by":"crossref","first-page":"6209","DOI":"10.1093\/nar\/gkt200","article-title":"Molecular basis for improved gene silencing by Dicer substrate interfering RNA compared with other siRNA variants","volume":"41","author":"Snead","year":"2013","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtn.2025.102773_bib21","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1093\/jleuko\/qiae059","article-title":"Optimization of a lipid nanoparticle-based protocol for RNA transfection into primary mononuclear phagocytes","volume":"115","author":"Zhang","year":"2024","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.omtn.2025.102773_bib22","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jconrel.2019.09.011","article-title":"Lipid nanoparticles of Type-A CpG D35 suppress tumor growth by changing tumor immune-microenvironment and activate CD8 T cells in mice","volume":"313","author":"Munakata","year":"2019","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.omtn.2025.102773_bib23","doi-asserted-by":"crossref","first-page":"3018","DOI":"10.3389\/fimmu.2019.03018","article-title":"Lipid Nanoparticles Potentiate CpG-Oligodeoxynucleotide-Based Vaccine for Influenza Virus","volume":"10","author":"Shirai","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omtn.2025.102773_bib24","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/s41565-020-0669-6","article-title":"Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR-Cas gene editing","volume":"15","author":"Cheng","year":"2020","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.omtn.2025.102773_bib25","doi-asserted-by":"crossref","first-page":"19737","DOI":"10.1073\/pnas.1917424117","article-title":"Specific targeting of ovarian tumor-associated macrophages by large, anionic nanoparticles","volume":"117","author":"Haber","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtn.2025.102773_bib26","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1021\/acs.bioconjchem.1c00139","article-title":"Large, anionic liposomes enable targeted intraperitoneal delivery of a TLR 7\/8 agonist to repolarize ovarian tumors\u2019 microenvironment","volume":"32","author":"Kang","year":"2021","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.omtn.2025.102773_bib27","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abg3551","article-title":"Tumor-draining lymph nodes: At the crossroads of metastasis and immunity","volume":"6","author":"du Bois","year":"2021","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.omtn.2025.102773_bib28","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/s41568-021-00346-0","article-title":"Therapeutic cancer vaccines","volume":"21","author":"Saxena","year":"2021","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.omtn.2025.102773_bib29","doi-asserted-by":"crossref","first-page":"8576","DOI":"10.4049\/jimmunol.181.12.8576","article-title":"IL-12 produced by dendritic cells augments CD8+ T cell activation through the production of the chemokines CCL1 and CCL17","volume":"181","author":"Henry","year":"2008","journal-title":"J. Immunol."},{"key":"10.1016\/j.omtn.2025.102773_bib30","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.trecan.2018.09.001","article-title":"The role of type 1 conventional dendritic cells in cancer immunity","volume":"4","author":"B\u00f6ttcher","year":"2018","journal-title":"Trends Cancer"},{"key":"10.1016\/j.omtn.2025.102773_bib31","article-title":"In Situ Tumor Vaccination with Nanoparticle Co-Delivering CpG and STAT3 siRNA to Effectively Induce Whole-Body Antitumor Immune Response","volume":"33","author":"Ngamcherdtrakul","year":"2021","journal-title":"Adv. Mater."},{"key":"10.1016\/j.omtn.2025.102773_bib32","doi-asserted-by":"crossref","first-page":"4755","DOI":"10.1039\/D1BM00531F","article-title":"A nucleic acid nanogel dually bears siRNA and CpG motifs for synergistic tumor immunotherapy","volume":"9","author":"Zhang","year":"2021","journal-title":"Biomater. Sci."},{"key":"10.1016\/j.omtn.2025.102773_bib33","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1038\/s41467-017-01386-7","article-title":"Intertwining DNA-RNA nanocapsules loaded with tumor neoantigens as synergistic nanovaccines for cancer immunotherapy","volume":"8","author":"Zhu","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtn.2025.102773_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2025.113764","article-title":"Polymersome-enabled brain codelivery of STAT3 siRNA and CpG oligonucleotide boosts chemo-immunotherapy of malignant glioma","volume":"383","author":"Zhao","year":"2025","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.omtn.2025.102773_bib35","doi-asserted-by":"crossref","first-page":"8086","DOI":"10.1074\/jbc.M410868200","article-title":"Spontaneous formation of nucleic acid-based nanoparticles is responsible for high interferon-alpha induction by CpG-A in plasmacytoid dendritic cells","volume":"280","author":"Kerkmann","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.omtn.2025.102773_bib36","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1208\/s12248-010-9210-4","article-title":"Delivery of siRNA therapeutics: barriers and carriers","volume":"12","author":"Wang","year":"2010","journal-title":"AAPS J."},{"key":"10.1016\/j.omtn.2025.102773_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2022.114416","article-title":"The role of lipid components in lipid nanoparticles for vaccines and gene therapy","volume":"188","author":"Hald Albertsen","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.omtn.2025.102773_bib38","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jconrel.2014.09.025","article-title":"Development of lipid nanoparticle formulations of siRNA for hepatocyte gene silencing following subcutaneous administration","volume":"196","author":"Chen","year":"2014","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.omtn.2025.102773_bib39","doi-asserted-by":"crossref","first-page":"2998","DOI":"10.1158\/2159-8290.CD-21-0425","article-title":"Overcoming PD-1 Blockade Resistance with CpG-A Toll-Like Receptor 9 Agonist Vidutolimod in Patients with Metastatic Melanoma","volume":"11","author":"Ribas","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.omtn.2025.102773_bib40","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1158\/2159-8290.CD-18-0743","article-title":"In Situ Vaccination with a TLR9 Agonist and Local Low-Dose Radiation Induces Systemic Responses in Untreated Indolent Lymphoma","volume":"8","author":"Frank","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.omtn.2025.102773_bib41","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1038\/nri1961","article-title":"Interferons, immunity and cancer immunoediting","volume":"6","author":"Dunn","year":"2006","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.omtn.2025.102773_bib42","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/s41573-021-00163-y","article-title":"Emerging concepts in the science of vaccine adjuvants","volume":"20","author":"Pulendran","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.omtn.2025.102773_bib43","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1084\/jem.20060401","article-title":"Properties regulating the nature of the plasmacytoid dendritic cell response to Toll-like receptor 9 activation","volume":"203","author":"Guiducci","year":"2006","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.omtn.2025.102773_bib44","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1038\/s41416-022-01876-6","article-title":"Toll-like receptor 9 agonists and combination therapies: strategies to modulate the tumour immune microenvironment for systemic anti-tumour immunity","volume":"127","author":"Dongye","year":"2022","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.omtn.2025.102773_bib45","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.jconrel.2022.03.046","article-title":"The replacement of helper lipids with charged alternatives in lipid nanoparticles facilitates targeted mRNA delivery to the spleen and lungs","volume":"345","author":"LoPresti","year":"2022","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.omtn.2025.102773_bib46","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1172\/JCI200113903","article-title":"Is the class A macrophage scavenger receptor (SR-A) multifunctional? - The mouse\u2019s tale","volume":"108","author":"Platt","year":"2001","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.omtn.2025.102773_bib47","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.coi.2005.11.008","article-title":"The mononuclear phagocyte system","volume":"18","author":"Hume","year":"2006","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.omtn.2025.102773_bib48","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/s41577-022-00737-w","article-title":"Myeloid cell-targeted therapies for solid tumours","volume":"23","author":"Goswami","year":"2023","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.omtn.2025.102773_bib49","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.3389\/fimmu.2020.01066","article-title":"Phagocytosis: our current understanding of a universal biological process","volume":"11","author":"Uribe-Querol","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omtn.2025.102773_bib50","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1038\/s41565-020-0719-0","article-title":"Role of nanoscale antigen organization on B-cell activation probed using DNA origami","volume":"15","author":"Veneziano","year":"2020","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.omtn.2025.102773_bib51","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/nyas.12137","article-title":"Human B-1 cells take the stage","volume":"1285","author":"Rothstein","year":"2013","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.omtn.2025.102773_bib52","doi-asserted-by":"crossref","first-page":"21733","DOI":"10.1039\/C9NR09347H","article-title":"On the role of helper lipids in lipid nanoparticle formulations of siRNA","volume":"11","author":"Kulkarni","year":"2019","journal-title":"Nanoscale"},{"key":"10.1016\/j.omtn.2025.102773_bib53","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.vaccine.2015.10.132","article-title":"A novel lipid nanoparticle adjuvant significantly enhances B cell and T cell responses to sub-unit vaccine antigens","volume":"34","author":"Swaminathan","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.omtn.2025.102773_bib54","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1038\/s41590-022-01160-y","article-title":"IL-1 and IL-1ra are key regulators of the inflammatory response to RNA vaccines","volume":"23","author":"Tahtinen","year":"2022","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.omtn.2025.102773_bib55","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.immuni.2005.09.010","article-title":"IL-6-STAT3 controls intracellular MHC class II alphabeta dimer level through cathepsin S activity in dendritic cells","volume":"23","author":"Kitamura","year":"2005","journal-title":"Immunity"},{"key":"10.1016\/j.omtn.2025.102773_bib56","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.tox.2005.07.023","article-title":"Complement activation-related pseudoallergy: a new class of drug-induced acute immune toxicity","volume":"216","author":"Szebeni","year":"2005","journal-title":"Toxicology"},{"key":"10.1016\/j.omtn.2025.102773_bib57","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/j.2040-4603.2019.tb00063.x","article-title":"Lymphatic vessel network structure and physiology","volume":"9","author":"Breslin","year":"2018","journal-title":"Compr. Physiol."},{"key":"10.1016\/j.omtn.2025.102773_bib58","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1021\/acs.molpharmaceut.9b01182","article-title":"The effect of size and charge of lipid nanoparticles prepared by microfluidic mixing on their lymph node transitivity and distribution","volume":"17","author":"Nakamura","year":"2020","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.omtn.2025.102773_bib59","doi-asserted-by":"crossref","first-page":"8304","DOI":"10.1021\/acs.nanolett.2c03234","article-title":"Phosphatidylserine lipid nanoparticles promote systemic RNA delivery to secondary lymphoid organs","volume":"22","author":"Luozhong","year":"2022","journal-title":"Nano Lett."}],"container-title":["Molecular Therapy Nucleic Acids"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253125003270?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253125003270?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T16:14:59Z","timestamp":1773850499000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2162253125003270"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":59,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S2162253125003270"],"URL":"https:\/\/doi.org\/10.1016\/j.omtn.2025.102773","relation":{},"ISSN":["2162-2531"],"issn-type":[{"value":"2162-2531","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Myeloid cell-targeted lipid nanoparticles for B cell lymphoma immunotherapy","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Nucleic Acids","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtn.2025.102773","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"102773"}}